A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
about
Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Contemporary approaches for imaging skeletal metastasisAnti-angiogenesis in prostate cancer: knocked down but not outClinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selectionReceptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancersBone Metastases: An Overview.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceCTC enumeration and characterization: moving toward personalized medicine.A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.Tumor and Plasma Met Levels in Non-Metastatic Prostate Cancer.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancerBone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.Development of cabozantinib for the treatment of prostate cancer.Circulating tumour cells-monitoring treatment response in prostate cancer.Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies.Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view.A phase I study of cabozantinib (XL184) in patients with renal cell cancer.Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Cabozantinib in genitourinary malignancies.Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Circulating tumor cells in prostate cancer: Precision diagnosis and therapyMET expression during prostate cancer progression.Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.[New therapy concepts for castration-resistant prostate cancer: between hormone manipulation, targeted therapy and chemotherapy].
P2860
Q26747566-C64B17DC-413D-406E-88D6-F960AE47C89AQ26798170-E13D35D6-2DC7-4713-913E-279E1D2EBBD2Q26851183-1643B317-9317-4CB8-8CEC-A04C4A9ED0E1Q28074834-1106CF69-2CE3-4D45-992C-7C22A1EA05EEQ28082793-4D4D9CF1-C124-41E5-A00C-1304FDBCC48DQ33727278-EEA4E5B4-1739-41B7-A0DA-59C5BA8A8D21Q33769437-A6544F63-0D95-458E-9E7C-51419AD4BE5BQ33880064-890D18A4-CD82-4BF3-A499-9AF9D7F46943Q34108738-8E529CD8-AB45-44F4-8D94-063353B8F274Q34330748-609F1744-140E-4377-BEEA-5F6703EDA1A8Q34448130-6CAD8C4C-D68D-44ED-810C-B1144C3592C9Q34505037-8D86D986-780B-468E-98CF-9F0626B6C431Q34577724-606FF520-BB4B-45B4-84E6-DF136024AE43Q34657338-9897E42A-3796-4E95-869D-38FDD2202994Q34987693-C43D99EF-9BDE-4DC5-A792-646BCCF9EA05Q35252908-4D74AE64-7AA6-4E9C-BBD6-E3228B0F3B4BQ35985270-5F879BCE-E9C9-4DA6-AB17-9D3A76D844D0Q36051783-58815503-74EE-4386-99AA-1A91015C36D8Q36156854-37ACE849-0FD9-4557-A7E8-3096B2CC13FBQ36436763-40EF65FB-3B86-41E5-9471-9D238C7C9B50Q36931715-62EC7A49-C3F5-4BC6-A7C7-956558BFC382Q37166534-07A80105-C7E5-4415-9055-7C445611230DQ37665068-71E6FEE9-897A-4E38-9058-41EA72AE4534Q38160757-DEC150A6-492D-4D91-BF81-9013E10E9169Q38177689-DB614843-DA26-4748-847B-D01CD3FFA807Q38208820-5602F9F1-B579-491B-9C6B-6D9755ADA396Q38211361-339BE921-5B6F-449B-84FF-73695E74F30BQ38244522-CA6E9937-5531-49D8-999F-B400394E5B92Q38263563-CD95D508-EA5D-47D0-8687-0FDD17486A1BQ38430335-D14A777B-ADE7-42E7-8E7A-BE3872FFA5A9Q38723404-8B40B480-5524-4C34-A94C-448994518165Q38746778-E1C3BF40-1780-4AC3-8C4C-24A27F3D5538Q38795560-873BC85B-F106-4787-87DE-1F61524A17CDQ38822335-B09A6707-FC66-410B-B208-209E368148DCQ38907580-E9377686-1750-4A5C-A08E-50C9F5F26279Q41142322-8088CFC3-9493-4271-B60D-D4D08E230DE8Q41418443-FAB30361-4A70-42B0-9EE0-ADA423E60A5EQ42530532-1DEB07C1-1F21-4EE9-A6D7-EEBE20D9C334Q47940756-B2EC7ABB-5AF2-4344-A436-4646106A69BEQ54685484-AA49E5F8-C489-44B8-95D9-8042ABBD49D1
P2860
A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A dose-ranging study of caboza ...... te cancer and bone metastases.
@en
type
label
A dose-ranging study of caboza ...... te cancer and bone metastases.
@en
prefLabel
A dose-ranging study of caboza ...... te cancer and bone metastases.
@en
P2093
P2860
P1476
A dose-ranging study of caboza ...... te cancer and bone metastases.
@en
P2093
Carol A Gurski
Daniel A Haber
David T Miyamoto
Jonathan G Goldin
M Dror Michaelson
Malgorzata E Smas
Matthew R Smith
Philip J Saylor
Richard J Lee
S Michael Rothenberg
P2860
P304
P356
10.1158/1078-0432.CCR-13-0319
P407
P577
2013-04-03T00:00:00Z